Modality
Nanobody
MOA
SGLT2i
Target
DLL3
Pathway
Complement
Bladder CaHSEpilepsy
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
~Jun 2019
→ ~Sep 2020
Phase 3
~Dec 2020
→ ~Mar 2022
NDA/BLA
~Jun 2022
→ ~Sep 2023
Approved
Dec 2023
→ Dec 2029
ApprovedCurrent
NCT08802678
2,326 pts·Bladder Ca
2023-12→2029-12·Terminated
2,326 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-12-173.7y awayPh3 Readout· Bladder Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2029-12-17 · 3.7y away
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08802678 | Approved | Bladder Ca | Terminated | 2326 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |